Cytomegalovirus Native Protein
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-62435
Key Product Details
Conjugate
Unconjugated
Applications
ELISA
Product Specifications
Description
Native cytomegalovirus strain AD-169, cultured in MRC-5, a diploid cell line of human lung origin.
Source:Cytomegalovirus
Protein / Peptide Type
Native Protein
Formulation, Preparation and Storage
NBP2-62435
| Preparation Method | MRC-5 monolayers are infected in a manner which will ensure that the full host of viral proteins are present upon harvest. Optimally infected tissue is collected in glycine buffered saline. The cells are disrupted to release cellular CMV antigen. Cellular |
| Formulation | Glycine buffered saline |
| Preservative | No Preservative |
| Concentration | 3.5 mg/ml |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Store at -70C. Avoid freeze-thaw cycles. |
Background: Cytomegalovirus
Cytomegalovirus is a common virus, infecting ~60% of adults in developed countries and over 90% in developing countries, as indicated by presence of specific IgG antibodies (2-4). Although a majority of people infected remain asymptomatic, immunocompromised people, organ transplant recipients, and fetuses and newborns are more susceptible to HCMV-associated diseases (1-4). Annually, up to 2% of newborns are born with HCMV, making it the most common congenital infection (2-4). Cytomegalovirus is known to cause sensorineural hearing loss (SNHL), mental retardation, chorioretinitis, skin lesions, as well as end organ disease (3,5). There are a few CMV therapeutics approved by FDA including valganciclovir and letermovir; however, despite some benefits, there is the need for new antivirals and combination therapies (5). Potential new treatment options include monoclonal antibodies and sirtuins (5).
References
1. Connolly SA, Jardetzky TS, Longnecker R. The structural basis of herpesvirus entry. Nat Rev Microbiol. 2021;19(2):110-121. https://doi.org/10.1038/s41579-020-00448-w
2. Griffiths P, Reeves M. Pathogenesis of human cytomegalovirus in the immunocompromised host. Nat Rev Microbiol. 2021;19(12):759-773. https://doi.org/10.1038/s41579-021-00582-z
3. Krstanovic F, Britt WJ, Jonjic S, Brizic I. Cytomegalovirus Infection and Inflammation in Developing Brain. Viruses. 2021;13(6):1078. Published 2021 Jun 4. https://doi.org/10.3390/v13061078
4. Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235(2):288-297. https://doi.org/10.1002/path.4437
5. Acosta E, Bowlin T, Brooks J, et al. Advances in the Development of Therapeutics for Cytomegalovirus Infections. J Infect Dis. 2020;221(Suppl 1):S32-S44. https://doi.org/10.1093/infdis/jiz493
Alternate Names
CMV; HHV 5; HHV5; Human herpesvirus 5
Additional Cytomegalovirus Products
Product Documents for Cytomegalovirus Native Protein
Product Specific Notices for Cytomegalovirus Native Protein
This product is for research use only and is not approved for use in humans or in clinical diagnosis. This product is guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...